Hope for rare fat disorder: drug keeps working in Long-Term study
NCT ID NCT02262806
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 7 times
Summary
This study gives the drug metreleptin to 29 people with partial lipodystrophy, a rare condition that causes high blood fats and diabetes. Participants have already shown improvement from the drug in earlier studies. The goal is to keep providing the treatment and check its long-term safety and effectiveness with regular blood tests and exams.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could diabetes be silently damaging your hearing?
- Press play on better health: could recording doctor visits boost Self-Care in seniors?
- Could a simple breakfast replace the glucose drink for diabetes testing?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- A simple card game could transform diabetes care